Literature DB >> 24630536

Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer.

Stine Elleberg Petersen1, Lise Bentzen2, Katrine J Emmertsen3, Søren Laurberg3, Lilli Lundby3, Morten Høyer2.   

Abstract

PURPOSE: To develop and validate a scoring system for evaluation of long term anorectal dysfunction following radiotherapy for prostate cancer.
MATERIALS AND METHODS: Patients treated for prostate cancer with radiotherapy filled in questionnaires on anorectal function and quality of life. Items for the condensed anorectal dysfunction score (RT-ARD) were identified and weighted by binomial regression analysis. The score was tested in a separate patient material by receiver operating characteristic (ROC) analysis and correlations to quality of life domains.
RESULTS: A total of 309 patients participated in the study. The items selected were "incontinence for solid stool", "ability to defer defecation", "unproductive call to stool", "clustering of stool", and "mucus in stool." Patients were grouped into three categories according to the RT-ARD score; 0-8 (no RT-ARD), 9-23 (minor RT-ARD), 24-45 (major RT-ARD). ROC analyses revealed high sensitivity (91%) and specificity (85%) for major RT-ARD. The prediction model demonstrated a perfect fit in 60%, moderate fit in 36% and no fit in 4%. There was good correlation between the RT-ARD score and quality of life.
CONCLUSIONS: The RT-ARD score is a validated and simple instrument for evaluation of anorectal dysfunction following radiotherapy for prostate cancer, and the RT-ARD score correlates to the patient's quality of life.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Late morbidity; Prostate cancer; Quality of life; Radiotherapy

Mesh:

Year:  2014        PMID: 24630536     DOI: 10.1016/j.radonc.2014.01.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity.

Authors:  Michael Pinkawa; Carolina Ribbing; Victoria Djukic; Jens Klotz; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2015-05-26       Impact factor: 3.621

2.  Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy.

Authors:  Maria Thor; Caroline Olsson; Jung Hun Oh; Stine Elleberg Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig Paul Muren; Morten Høyer; Gunnar Steineck; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2016-02-12       Impact factor: 6.280

3.  Cucurbitacin E induces apoptosis of human prostate cancer cells via cofilin-1 and mTORC1.

Authors:  Xiaolong He; Qi Gao; Yayong Qiang; Wei Guo; Yadong Ma
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

4.  Reduced luminal circumference of tumors plays a key role in anorectal function during the early period after neoadjuvant chemoradiation therapy in rectal cancer patients.

Authors:  Bong-Hyeon Kye; Hyung-Jin Kim; Hyeon-Min Cho; Jun-Gi Kim; Sung Hwan Kim; Byoung-Yong Shim
Journal:  Int J Colorectal Dis       Date:  2015-02-25       Impact factor: 2.571

5.  Influence of image slice thickness on rectal dose-response relationships following radiotherapy of prostate cancer.

Authors:  C Olsson; M Thor; M Liu; V Moissenko; S E Petersen; M Høyer; A Apte; J O Deasy
Journal:  Phys Med Biol       Date:  2014-06-17       Impact factor: 3.609

6.  Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?

Authors:  M Bonet; L Cayetano; M Núñez; E Jovell-Fernández; A Aguilar; Y Ribas
Journal:  Clin Transl Oncol       Date:  2017-09-12       Impact factor: 3.405

7.  Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor
Journal:  Acta Oncol       Date:  2017-09-08       Impact factor: 4.089

8.  Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer.

Authors:  Maria Thor; Caroline E Olsson; Jung Hun Oh; Stine E Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig P Muren; Ann-Charlotte Waldenström; Morten Høyer; Gunnar Steineck; Joseph O Deasy
Journal:  Acta Oncol       Date:  2015-09-04       Impact factor: 4.089

9.  Normal tissue complication probability models for prospectively scored late rectal and urinary morbidity after proton therapy of prostate cancer.

Authors:  Jesper Pedersen; Xiaoying Liang; Curtis Bryant; Nancy Mendenhall; Zuofeng Li; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2021-11-08

10.  AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases.

Authors:  Liv Marit Valen Schougaard; Louise Pape Larsen; Anne Jessen; Per Sidenius; Liv Dorflinger; Annette de Thurah; Niels Henrik Hjollund
Journal:  Qual Life Res       Date:  2016-01-20       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.